Marinus Pharmaceuticals to Host Pipeline Update Webinar

RADNOR, Pa., June 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and commercial overview on its pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex. In addition, there will be four key opinion leaders participating in the event, which will take place on Tuesday, June 30, 2020 from 8am – 10.30am Eastern Time.

Preliminary Agenda:

Marinus Overview			Dr. Scott Braunstein, Chief Executive Officer
Status Epilepticus			Dr. Joe Hulihan, Chief Medical Officer Dr. Larry Hirsch, Yale Comprehensive Epilepsy Center Dr. Henrikas Vaitkevicius, Brigham and Women’s Hospital Department of Neurology Dr. Alex Aimetti, Head of Scientific Affairs
CDD Overview			Dr. Scott Demarest, Children’s Hospital Colorado
			Dr. Joe Hulihan, Chief Medical Officer
Tuberous Sclerosis			Dr. Darcy Krueger, Cincinnati Children’s Hospital Medical Center
Complex Overview			Dr. Alex Aimetti, Head of Scientific Affairs
Commercial Strategy			Thomas Lyons, Vice President of Business Development & Licensing

To register in advance and listen to the live webinar please click here.